RAYMOND KNOX JOINS VAXESS TO LEAD PREPARATION FOR COMMERCIAL-SCALE MANUFACTURING AS VAXESS ADVANCES ITS GLP-1 PROGRAM

WOBURN, Mass, September 17, 2025 — Vaxess Technologies, Inc., a biotech company developing a novel microarray patch technology to transform home delivery of therapies, today announced Raymond Knox as its vice president of manufacturing.

“As Vaxess continues to receive encouraging data related to administering GLP-1 via Vaxess’s microarray patch, the company’s manufacturing focus is on laying the groundwork to scale,” said Rachel Sha, CEO of Vaxess. “Our team has done extraordinary work in setting up Vaxess’s first GMP manufacturing facility in Woburn. Ray brings the expertise we need as Vaxess plans to increase production at its current facility, and looks towards building additional facilities as well as contracting with other manufacturers. We want to ensure the manufacturing investments Vaxess makes today will position the company for commercial-scale manufacturing in the years to come.”

With more than three decades of experience in biotech manufacturing and product development, Knox has a proven record of success across both large multi-billion-dollar organizations and early-stage companies. Most recently, Knox served as chief manufacturing officer at Lyndra Therapeutics. Previously, he held several senior positions at Ximedica (now part of Veranex), 480 Biomedical, and Boston Scientific. He began his career in engineering and product development roles at Medtronic, C.R. Bard, and Becton Dickinson, and today continues to serve a board of trustee position for Massachusetts Biomedical Initiatives (MBI).

“It’s a privilege to join a team that is advancing improving the patient experience of administering next-generation therapies like GLP-1, and to help translate breakthrough science into commercial reality,” said Knox. “My focus is to build the systems, automation, and supply chain needed for microarray patch production at the scale of hundreds of thousands, and ultimately millions, of patches per year.”

Knox is joining Vaxess during a time of significant growth for the company. Recent milestones include:

• Presenting new preclinical data at the 2025 American Diabetes Association (ADA) Scientific Sessions in Chicago: Vaxess’s research demonstrates that the company’s microarray patch (MAP) is capable of delivering semaglutide, a GLP-1 receptor agonist, with bioavailability comparable to subcutaneous injection.

• Raising additional funding: In the first half of 2025, Vaxess raised funding from RA Capital Management and Engine Ventures. Vaxess is using this funding to continue to advance its work in GLP-1, and expand manufacturing capabilities to support the lead program and new partnerships for additional therapeutics.

About Vaxess

Vaxess Technologies is transforming home delivery of next generation therapies.

Vaxess's platform combines a proprietary microarray patch and applicator, capable of delivering a wide range of therapies. Advanced biomaterials used for the dissolvable microarray tips enable the greatest levels of dose delivery control, and can be modified to deliver different payloads. Additionally, the patch does not require refrigeration, enabling delivery to low resource settings.

Vaxess has raised more than $100 million in grant and venture capital funding from groups such as RA Capital Management, Engine Ventures, GHIC, Mission BioCapital, BARDA, DARPA, NIH, NSF and the Gates Foundation. The company has also generated strong clinical and in-vivo proof of concept in the platform with a wide range of molecules. For more information, please visit the company website at www.vaxess.com or send additional inquiries to contact@vaxess.com.